<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552888</url>
  </required_header>
  <id_info>
    <org_study_id>TulaneU</org_study_id>
    <secondary_id>1U54GM104940</secondary_id>
    <nct_id>NCT02552888</nct_id>
  </id_info>
  <brief_title>Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial</brief_title>
  <acronym>NICE</acronym>
  <official_title>Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed randomized controlled trial will test the safety and efficacy of combination
      therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among
      patients with chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed randomized controlled trial will test the safety and efficacy of combination
      therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among
      patients with chronic kidney disease. Investigators will recruit 70 albuminuric CKD patients
      and randomly assign participants to combination therapy with sodium nitrite and isoquercetin
      or placebo for three months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelium-dependent flow-mediated vasodilation (FMD)</measure>
    <time_frame>3 months</time_frame>
    <description>FMD will be measured using high resolution ultrasound on the brachial artery,FMD will be calculated as the maximal percentage change in vessel size during hyperemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endothelial function biomarkers</measure>
    <time_frame>3 months</time_frame>
    <description>ADMA, ICAM-1, VCAM-1, E-selectin, vWF, and endostatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory biomarkers</measure>
    <time_frame>3 months</time_frame>
    <description>CRP, TNF-α, IL-6, IL-1β and MCP-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidative stress biomarkers</measure>
    <time_frame>3 months</time_frame>
    <description>oxidized LDL and nitrotyrosines</description>
  </secondary_outcome>
  <other_outcome>
    <measure>methemoglobin levels</measure>
    <time_frame>3 months</time_frame>
    <description>blood methemoglobin levels</description>
  </other_outcome>
  <other_outcome>
    <measure>isoquercetin levels</measure>
    <time_frame>3 months</time_frame>
    <description>blood isoquercetin levels</description>
  </other_outcome>
  <other_outcome>
    <measure>plasma level of nitrite</measure>
    <time_frame>3 months</time_frame>
    <description>plasma level of nitrite</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose-6-phosphate dehydrogenase level</measure>
    <time_frame>3 months</time_frame>
    <description>blood Glucose-6-phosphate dehydrogenase level</description>
  </other_outcome>
  <other_outcome>
    <measure>estimated-glomerular filtration rate</measure>
    <time_frame>3 months</time_frame>
    <description>estimated-glomerular filtration rate (mL/min/1.73 m2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3 months</time_frame>
    <description>Blood pressure (mm Hg)</description>
  </other_outcome>
  <other_outcome>
    <measure>blood chemistry panel</measure>
    <time_frame>3 months</time_frame>
    <description>blood glucose, urea nitrogen, creatinine, calcium, phosphorus, bicarbonate</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid panel</measure>
    <time_frame>3 months</time_frame>
    <description>cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol</description>
  </other_outcome>
  <other_outcome>
    <measure>complete blood count</measure>
    <time_frame>3 months</time_frame>
    <description>complete blood count</description>
  </other_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>nitrate</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma nitrate levels</description>
  </other_outcome>
  <other_outcome>
    <measure>urinary albumin-to-creatinine ratios</measure>
    <time_frame>3 months</time_frame>
    <description>urinary albumin-to-creatinine ratios(mg/g).</description>
  </other_outcome>
  <other_outcome>
    <measure>pulse</measure>
    <time_frame>3 months</time_frame>
    <description>pulse (beats/minute)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>identical placebos.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate release sodium nitrite</intervention_name>
    <description>Immediate release sodium nitrite 40 mg by mouth twice per day</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>TV1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isoquercetin</intervention_name>
    <description>Isoquercetin 225 mg by mouth once per day</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>3-O-glucoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebos</intervention_name>
    <description>placebos</description>
    <arm_group_label>Placebos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 21-74 years old with any race/ethnicity background

          -  CKD as defined by an eGFR &lt;60 ml/min/1.73 m2 or urinary albumin to creatinine ratio ≥
             30 mg/g or protein to creatinine ratio ≥150 mg/g.

          -  Systolic BP≥120 and &lt;180 mmHg and/or diastolic BP≥70 and &lt;110 mmHg

        Exclusion Criteria:

          -  Allergic to organic nitrite, isoquercetin, niacin, or vitamin C

          -  Institutionalized (e.g., prisoner, nursing home or skilled nursing facility resident)

          -  Unable or unwilling to give consent

          -  Known HIV infection and/or AIDS

          -  Pregnant or lactating women

          -  Currently on dialysis

          -  Previous or current organ or bone marrow transplant

          -  Receiving immunosuppressive treatment or other immunotherapy

          -  Receiving chemotherapy or alkylating agents for systemic cancer

          -  Recent acute myocardial infarction, cerebrovascular accidence or transient ischemic
             attack, or hospitalization in 3 months

          -  Acute kidney injury within the previous 3 months

          -  Currently taking a phosphodiesterase-5 enzyme inhibitor, such as Viagra

          -  History of chronic headaches

          -  Chronically receiving fluoroguinolones, cyclosporin (neural, sandimmune), nitrate
             drug, NSAIDS ( except aspirin ≤ 81 mg daily), allopurinol or uloric, meperidine and
             related central nervous system (CNS) depressants, oral glucocorticoids, and not
             willing or able to stop during study period.

          -  Active infection (i.e. systemic or osteomyelitis)

          -  Class III or IV heart failure

          -  History of hemolytic anemia including sickle cell disease

          -  Hemoglobin &lt;10

          -  History of chronic obstructive pulmonary disease (COPD)

          -  Have a positive screen for glucose-6-phosphate dehydrogenase (G6PD) deficiency at
             screening

          -  Involvement in other clinical trials

          -  Current alcohol or other substance abuse

          -  Current smokers

          -  Unwillingness to stop flavonoid supplementation

          -  Unwillingness to stop nitrate and/or nitrite supplementation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University</investigator_affiliation>
    <investigator_full_name>Jing Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

